Supernus Pharmaceuticals (SUPN) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Supernus Pharmaceuticals

NasdaqGM•Healthcare•Drug Manufacturers - Specialty & Generic

$41.21-0.02(<0.01%)Pre-market

Market Cap

$1.64B

P/S

1.9x

P/B

1.5x

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit/hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia in patients with Parkinson's disease (PD) receiving levodopa/carbidopa; Oxtellar XR, an extended-release oxcarbazepine product indicated for monotherapy for partial-onset seizures; ZURZUVAE, a neuroactive steroid with GABAergic activity, for the treatment of postpartum depression (PPD) in adults; and APOKYN for the acute, intermittent treatment of hypomobility or off-episodes in patients with advanced PD. It also provides Trokendi XR, an extended-release topiramate product indicated for the treatment of epilepsy and for migraine prophylaxis; XADAGO for use with levodopa/carbidopa in patients with PD experiencing off-episodes; and MYOBLOC, a type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor in a Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in a Phase 2 clinical trial for treatment-resistant depression; and SPN-443, a stimulant in a Phase 1 trial for the treatment of ADHD and other CNS conditions. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of a Phase 2 clinical program for SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland. As of November 2, 2026, Supernus Pharmaceuticals, Inc. operates as a subsidiary of Indivior Pharmaceuticals, Inc.

How this company scores

GoodMetricSide Score: 60/100

Strongest: Growth (17/25); weakest: Profitability (11/25).

Profitability11/25

Growth17/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality17/25

Strengths

Growing revenueRising free cash flowLong cash runwayInterest easily covered

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 12.8x5y range 8.6x – 634.1x

Currently below its 14-quarter median.

P/S · 1.9x5y range 0.8x – 2.9x

Currently near its 20-quarter median.

P/B · 1.5x5y range 0.5x – 2.3x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

FCF consistently trails net income (avg -3.6x) — earnings may be inflated by non-cash items or aggressive accounting.

Price & Volume

Market Cap $1.64B

Metrics at a Glance

as of September 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $865.11M
Q. Revenue: $226.77M
TTM EBITDA: $51.47M
TTM Op. Income: $-49.05M
Q. Op. Income: $21.18M
TTM Net Income: $-43.86M
Q. Net Income: $20.91M
EPS: $0.36
Shares Out.: $58.20M

$865.11M in TTM revenue grew 26.9% YoY, reaching $226.77M last quarter. TTM EBITDA of $51.47M and TTM operating income of $-49.05M show growth is flowing through to the bottom line. However, net income is negative at $43.86M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has risen for 5 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 88.1%
EBITDA Margin: 19.8%
Op. Margin: 9.3%
Net Margin: 9.2%

Op. margin of 9.3% is up 40.7% YoY — cost efficiency is improving. Net margin at 9.2% and gross margin of 88.1% show how much of each revenue dollar survives to profit. Over the past year, operating margin is up 130% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 1.9x
P/B Ratio: 1.5x

P/S of 1.9x and P/B of 1.5x. P/S is low relative to typical market levels. Over the past year, P/E is up 0% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $1.40B
Cash: $175.88M
Long-Term Debt: N/A
Book Value: $1.06B
D/E Ratio: N/A
Debt/EBITDA: 0.0

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $6.61M
TTM Free Cash Flow: $86.96M
FCF Margin: 10.1%
FCF / Net Income: -2.0

TTM FCF of $86.96M on $6.61M in operating cash flow. The FCF / Net Income ratio of -2.0x means the business consumes cash — it is not yet self-funding. Over the past year, free cash flow is up 23% — an improving trend.